Lg Life Sciences, Limited

Lg Chemical Ltd.

Yamanouchi Pharmaceutical Company Ltd.

Skc Co., Ltd.

S-energy Co., Ltd.

Koo Lee

Soo Yong Chung

Sang Dae Lee

Dong Sup Shim

Hyun Min Lee

Sang Pil Moon

Sung Pil Choi

In Ae Ahn

Yong Hee Lee

Yeong Soo Oh

You Seung Shin

Sang Soo Kim

Yi Na Jeong

Mi Kyung Yun

Hyun Ho Lee

Sang Yeul Hwang

Cheol Won Park

Seong Won Hong

Seong Ryul Hwang

Won Hyuk Jung

Sun Hwa Lee

Hee Dong Park

Sang Koo Lee

Bong Chan Kim

Young Kwan Kim

Sang-Kyun Lee

Hyeon Joo Yim

Ki Nam Byun

Deog Young Choi

Cheol-Won Park

Suk Kyoon Yoon

Won-Hyuk Jung

Hyeon-Joo Yim

Sang-Koo Lee

Kyung-Ha Chung

Dong-Sup Shim

Yutaka Kondoh

Sang Hyup Lee

Ryoji Hirabayashi

Jung Ae Lee

Shugo Honda

Won Hee Lee

Hidetaka Kaku

Youn Hoa Kim

Sunki Lee

Heui-Sul Park

Jun-ichi Shishikura

Mi Sook Shin

Hiroyuki Ito

Min Kyung Yoon

Byeong Man Kim

In-Ae Ahn

Takeshi Kurama

Yong Hwa Ha

Youngduck Kim

Hyun-Ju Yoo

Oeuk Park

Jong-Yup Kim

Deog-Young Choi

Jae Chul Lee

Provided is a solar cell module comprising a back sheet including a reflective film including a deposited reflective layer including metal and having 2 or higher optical density (OD), and an UV blocking layer positioned below the reflective film and having 5% or lower transmittance of light at 380 nm wavelength.

Back sheet, method of manufacturing the same, solar cell module using the same and method of manufacturing solar cell

The present invention relates to a compound having a good agonistic activity to melanocortin receptor, or pharmaceutically acceptable salt or isomer thereof, and an agonistic composition for melanocortin receptor comprising the same as an active ingredient.

Melanocortin receptor agonists

The present invention relates a compound of formula 1, and pharmaceutically acceptable salt, hydrate, solvate, or isomer thereof effective as agonist of melanocortin receptor, and an agonistic composition of melanocortin receptor comprising the same as active ingredient.

The present invention relates to a compound of the following formula 1, pharmaceutically acceptable salt and isomer thereof effective as agonist of melanocortin receptor, and an agonistic composition of melanocortin receptor comprising the same as active ingredient.

The present invention provides a novel process for preparing a compound represented by the above formula 7, which is an important intermediate for an oral thrombin inhibitor, by one-pot reaction. In accordance with the present invention, the above intermediate for the thrombin inhibitor may be obtained in a high yield.

Process for preparing 5-aminomethyl-2-thiophenecarbonitrile HCl by one-pot reaction

The present invention relates to a compound having formula I:and pharmaceutically acceptable salts thereof. The compounds of formula I and pharmaceutical compositions containing them are of the class of thrombin inhibitors which are useful as anticoagulants.

Piperidine and azetidine thrombin inhibitors

The present invention relates to novel thrombin inhibitors that are useful as anticoagulants. More particularly, the present invention is directed to peptide derivatives having high antithrombotic activity and high oral bioavailability.

Orally available peptidic thrombin inhibitors

Thrombin inhibitors

The present invention relates to a novel selective thrombin inhibitor having the following formula (I), which is also effective by oral administration: ##STR1## in which R.sup.1 represents acetyl substituted with aryl or aryloxy, or represents sulfonyl substituted with substituted or unsubstituted aryl or N-containing heterocyclic group,

Selective thrombin inhibitors

Growing community of inventors

Daejeon, South Korea

Koo Lee